APPENDIX A: REMS Initial REMS approval: [removed]Most recent modification: [removed]NDA[removed]VICTOZA® (liraglutide [rDNA origin] injection) Novo Nordisk Inc.

First Page		Document Content
Peptide hormones Thyroid cancer Anti-diabetic drugs Diabetes Liraglutide Medullary thyroid cancer Thyroid neoplasm Multiple endocrine neoplasia type 2 Novo Nordisk Medicine Anatomy Endocrine system		APPENDIX A: REMS Initial REMS approval: [removed]Most recent modification: [removed]NDA[removed]VICTOZA® (liraglutide [rDNA origin] injection) Novo Nordisk Inc. Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 1,00 MB Share Document on Facebook

	ABLYNX ACHIEVES FIRST MILESTONE AS PART OF COLLABORATION WITH NOVO NORDISK   Multi-specific Nanobody candidate reached discovery milestone Ablynx to receive a €1 million success fee DocID: 1thLm - View Document
	Vedr test af skabelonsystem DocID: 1rjCQ - View Document
	SECT Tech Summary SECT Tech, LLC is an existing team of accomplished bioscience executives with complementary backgrounds and is part of the State of Connecticut’s CTNext economic development program (administered by C DocID: 1qPhd - View Document
	Novo Nordisk Fonden bevilliger 235 million kroner til forskning i stamceller Pressemeddelelse, 23. november, 2015 Novo Nordisk Fonden har bevilget 235 millioner kroner til styrkelse og udvidelse af Novo Nordisk Foundatio DocID: 1qJz7 - View Document
	Dear Friends, Our next meeting will be held at a new restaurant, Duplex, please note the following information: Date/Time: Wednesday, Dec 05, 2012, at 6:30 p.m. Location: Duplex Restaurant 8722 West 3rd St. Los Angeles, DocID: 1pXal - View Document